# US 2025/0367231 A1 · Multifunctional bioadhesive designed with chemical functionality induced sutured biological building blocks

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367231 A1
- Document ID: US20250367231A1
- Status: Published application
- Kind: A1
- Application number: 18/868,628
- Filed: 2023-06-15
- Published: 2025-12-04
- Earliest claimed: 2022-06-17
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Nasim Annabi; Avijit Baidya
- Web page: https://patentgrep.com/patent/US20250367231A1

## CPC

- A61K 31/785: Polymers containing nitrogen
- A61L 24/104: {Gelatin}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61L 24/0031: {Hydrogels or hydrocolloids}
- A61L 27/222: {Gelatin}
- A61L 27/26: Mixtures of macromolecular compounds
- A61L 27/38: {containing added animal cells (organs or tissue containing native cells A61L27/36)}
- A61L 2300/406: Antibiotics
- A61L 2300/41: Anti-inflammatory agents, e.g. NSAIDs
- A61L 2300/418: Agents promoting blood coagulation, blood-clotting agents, embolising agents
- A61L 2300/42: Anti-thrombotic agents, anticoagulants, anti-platelet agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

A neurotransmitter moiety, dopamine, was chemically modified with a nitro-group to explore its influence on synthesizing a multifunctional biomaterial for therapeutic applications. Chemically, by manipulating the aromatic-electron density. while nitro-group prevented the self-oxidation of catecholic domain. this facilitated the aromatic suturing of nitrocatechol moieties, forming a novel macromolecular structure. Incorporation of the sutured-nitrocatecholic moieties in a gelatin-based hydrogel introduced extended pi-electron delocalization mediated electroconductive microenvironment and maintained its adhesive properties originated from the catecholic domains, forming a multi-functional bioadhesive for tissue repairing. Embodiments of the invention include engineered hydrogels enriched with multi-mode noncovalent interactions and excellent mechano-physical properties that are useful for diverse biomedical applications.

## Claims

### Claim 1

A composition of matter comprising a hydrogel and a polymer comprising dopamine having a nitro (NO2) moiety coupled to an aromatic ring (“nDopa”).

### Claim 2 (depends on 1)

The composition of claim 1, wherein the nDopa further comprises a methacrylate moiety on the aromatic ring (“nMAD”).

### Claim 3 (depends on 2)

The composition of claim 2, wherein methacrylate moieties in the composition are coupled so as to form a polymeric backbone on which nDopa is disposed so as to facilitate chemical suturing of aromatic domains of nDopa molecules.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the polymeric backbones form sutured-nitrocatecholic strands of nDopa polymers (“S-nCAT”).

### Claim 5 (depends on 4)

The composition of claim 4, wherein the composition comprises a gelatin that forms a gelatin-based, S-nCAT/gelatin hydrogel (“S-nCAGE”).

### Claim 6 (depends on 5)

The composition of claim 5, further comprising a pharmaceutical excipient selected from the group consisting of a preservative, a tonicity adjusting agent, a detergent, a viscosity adjusting agent, a sugar and a pH adjusting agent.

### Claim 7 (depends on 5)

The composition of claim 5, wherein chemical moieties are disposed on the S-nCAGE such that it exhibits one or more of the following materials properties:
an ultimate strength of at least 50 kPa;
a tensile toughness of at least 1×104 Jm−3);
a tensile modulus of at least 40 kPa;
a Young's modulus of at least 100 kPa;
adhesive energies of at least 5 or 10 Jm−2;
ionic conductance of at least 1×10−3 S/m; and/or
an adhesive strength of at least 10, 20, 30 or 40 kPa.

### Claim 8 (depends on 5)

The composition of claim 5, further comprising one or more therapeutic agents selected from an anti-inflammatory agent, an agent that modulates coagulation, an antibiotic agent, or a chemotherapeutic agent.

### Claim 9 (depends on 5)

The composition of claim 5, further comprising mammalian cells.

### Claim 10

A method of making a hydrogel composition comprising sutured-nitrocatecholic dopamine polymers, the method comprising combining together a hydrogel and polymers comprising a polymeric backbone comprising nDopa disposed on the polymeric backbone so as to facilitate chemical suturing of aromatic domains of nDopa molecules; wherein the hydrogel and the polymers are combined so as to form sutured-nitrocatecholic nDopa polymers within the hydrogel composition.

### Claim 11 (depends on 10)

The method of claim 10, further comprising disposing in the hydrogel composition:
a pharmaceutical excipient selected from the group consisting of a preservative, a tonicity adjusting agent, a detergent, a viscosity adjusting agent, a sugar and a pH adjusting agent;
one or more therapeutic agents selected from an anti-inflammatory agent, an agent that modulates coagulation, an antibiotic agent, a chemotherapeutic agent; and/or
mammalian cells.

### Claim 12 (depends on 11)

The method of claim 11, wherein the hydrogel composition comprises a gelatin.

### Claim 13 (depends on 10)

The method of claim 10, wherein the hydrogel and the polymers are formed in an oxidative environment.

### Claim 14 (depends on 10)

The method of claim 10, wherein the nDopa comprises a methacrylate moiety coupled to the aromatic ring.

### Claim 15 (depends on 10)

The method of claim 10, wherein the hydrogel composition is made to exhibit one or more of the following materials properties:
an ultimate strength of at least 50 kPa;
a tensile toughness of at least 1×104 Jm−3);
a tensile modulus of at least 40 kPa;
a Young's modulus of at least 100 kPa;
adhesive energies of at least 5 or 10 Jm−2;
ionic conductance of at least 1×10−3 S/m; and/or
an adhesive strength of at least 10, 20, 30 or 40 kPa.

### Claim 16 (depends on 5)

A method of adhering a first wet tissue to a second wet tissue comprising disposing a S-nCAGE composition of claim 5 between the first wet tissue and the second wet tissue so as to couple the first wet tissue to the second wet tissue, and adhering the first wet tissue and the second wet tissue by using the S-nCAGE as an adhesive composition.

### Claim 17 (depends on 16)

The method of claim 16, wherein the first wet tissue and the second wet tissue are adhered in vivo.

### Claim 18 (depends on 16)

The method of claim 16, wherein the adhesive composition comprises:
a pharmaceutical excipient selected from the group consisting of a preservative, a tonicity adjusting agent, a detergent, a viscosity adjusting agent, a sugar and a pH adjusting agent;
and/or one or more therapeutic agents such as an anti-inflammatory agent, an agent that modulates coagulation, an antibiotic agent, a chemotherapeutic agent or the like; and/or
mammalian cells.

### Claim 19 (depends on 16)

The method of claim 16, wherein the method comprises a step in which moieties in the S-nCAGE are covalently crosslinked.

### Claim 20 (depends on 16)

The method of claim 16, wherein chemical moieties are disposed on the S-nCAGE such that it exhibits one or more of the following materials properties:
an ultimate strength of at least 50 kPa;
a tensile toughness of at least 1×104 Jm−3);
a tensile modulus of at least 40 kPa;
a Young's modulus of at least 100 kPa;
adhesive energies of at least 5 or 10 Jm−2;
ionic conductance of at least 1×10−3 S/m; and/or
an adhesive strength of at least 10, 20, 30 or 40 kPa.
